CoChat

Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials

Open access
Laranjeira, Fernanda O., de Andrade, Keitty R. C., Figueiredo, Ana C. M. G., Silva, Everton N., Pereira, Mauricio G. · 2018 · PLOS ONE

The DOI matches its Crossref record; 81 of the 83 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The comparison between long acting insulin analogues (LAIA) and human insulin (NPH) has been investigated for decades, with many randomized controlled trials (RCTs) and systematic reviews giving mixed results. This overlapping and contradictory evidence has increased uncertainty on coverage decisions at health systems level. AIM: To conduct an overview of systematic reviews and update existing reviews, preparing new meta-analysis to determine whether LAIA are effective for T1D patients compared to NPH. METHODS: We identified systematic reviews of RCTs that evaluated the efficacy of LAIA glargine or detemir, compared to NPH insulin for T1D, assessing glycated hemoglobin (A1C) and hypoglycemia. Data sources included Pubmed, Cochrane Library, EMBASE and hand-searching. The methodological quality of studies was independently assessed by two reviewers, using AMSTAR and Jadad scale. We found 11 eligible systematic reviews that contained a total of 25 relevant clinical trials. Two reviewers independently abstracted data. RESULTS: We found evidence that LAIA are efficacious compared to NPH, with estimates showing a reduction in nocturnal hypoglycemia episodes (RR 0.66; 95% CI 0.57; 0.76) and A1C (95% CI 0.23; 0.12). No significance was found related to severe hypoglycemia (RR 0.94; 95% CI 0.71; 1.24). CONCLUSION: This study design has allowed us to carry out the most comprehensive assessment of RCTs on this subject, filling a gap in diabetes research. Our paper addresses a question that is important not only for decision makers but also for clinicians.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0194801

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Flowchart of the study selection process for systematic reviews.
Fig 1 Flowchart of the study selection process for systematic reviews.CC BY · PubMed Central
Fig 2 Meta-analysis of outcomes assessed in this overview: A: glycated hemoglobin—A1C; B: general hypoglycemia; C: severe hypoglycemia; D: nocturnal hypoglycemia.
Fig 2 Meta-analysis of outcomes assessed in this overview: A: glycated hemoglobin—A1C; B: general hypoglycemia; C: severe hypoglycemia; D: nocturnal hypoglycemia.CC BY · PubMed Central
Fig 3 Publication bias analysis by Begg’s funnel plots. A. General hypoglycemia. B. Severe hypoglycemia. C. Nocturnal hypoglycemia. D A1C.
Fig 3 Publication bias analysis by Begg’s funnel plots. A. General hypoglycemia. B. Severe hypoglycemia. C. Nocturnal hypoglycemia. D A1C.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Research works printed but not linked: 10

  1. T William, 2016, American Diabetes Association standards of medical care in diabetes 2016, Diabetes Care, 39, S1
  2. A Szypowska, 2009, Better metabolic control, less hypoglycemia and less weight gain with insulin detemir versus NPH insulin in intensive insulin therapy for patients with type 1 diabetes. A meta-analysis, Diabetologia, 52, S387
  3. P Rossetti, 2003, Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime, Diabetes Care, 26, 1490, 10.2337/diacare.26.5.1490 · DOI · Paper page
  4. P Home, 2004, Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial, Diabetes Care, 27, 1081, 10.2337/diacare.27.5.1081 · DOI · Paper page
  5. P Home, 2003, Insulin detemir offers improved glycemic control, less weight gain, and flexible timing of administration compared to NPH insulin, Diabetes, 52, A122
  6. JD Russell, 2004, Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen, Clin Ther, 26, 724, 10.1016/s0149-2918(04)90072-0 · DOI · Paper page
  7. PC Bartley, 2008, Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial, Diabet Med, 25, 442, 10.1111/j.1464-5491.2007.02407.x · DOI · Paper page
  8. SL Bowker, 2005, Systematic review of indicators and measurements used in controlled studies of quality improvement for type 2 diabetes, Can J Diabetes, 29, 230
  9. DM Nathan, 2014, The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview, Diabetes care, 37, 9, 10.2337/dc13-2112 · DOI · Paper page
  10. RM Bergenstal, 2015, No difference in Major Adverse Cardiovascular Events (MACE plus) with Basal Insulin peglispro (BIL) vs comparator insulins in patients with type 1 or type 2 diabetes, Diabetologia, 58, S65

Cited by

See all 46

Metadata

Authors
Laranjeira, F. O., de Andrade, K. R. C., Figueiredo, A. C. M. G., Silva, E. N., & Pereira, M. G.
Affiliations
Universidade de Brasília (BR)
Venue
PLOS ONE
Published
2018-04-12
Volume
13
Issue
4
Pages
e0194801
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2796961649
Cited by
41
References
83
Citations by year
2025: 3 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 12 · 2020: 6 · 2019: 12
FWCI
1.15
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Americanae (AECID Library) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • RIUnB Institutional Repository (University of Brasília) (submittedVersion, cc-by)
Funders
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Ministério da Educação
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
long-acting insulin analogues, type 1 diabetes, insulin glargine, insulin detemir, NPH insulin, HbA1c, hypoglycemia, nocturnal hypoglycemia, severe hypoglycemia, insulin therapy comparison
MeSH terms
Insulin Glargine, Insulin Detemir, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Regression Analysis, Models, Statistical, Randomized Controlled Trials as Topic, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1371/journal.pone.0194801
The paper
Laranjeira, F. O., de Andrade, K. R. C., Figueiredo, A. C. M. G., Silva, E. N., & Pereira, M. G. (2018). Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials. PLOS ONE. https://doi.org/10.1371/journal.pone.0194801

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.